Newsfeeds Archive - Spark Newswire

2 minute read

Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024

December 29, 8:04 AM

According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023.

ABBV

2 minute read

EnerSys To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday

By Avi Kapoor

December 20, 8:50 AM

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

CPNG

3 minute read

Analyst Ratings

Analyst Expectations For Mirati Therapeutics’s Future

By Benzinga Insights

December 20, 8:00 AM

11 analysts have expressed a variety of opinions on Mirati Therapeutics (NASDAQ:MRTX) over the past quarter, offering a…

MRTX

4 minute read

Options

10 Health Care Stocks With Whale Alerts In Today’s Session

By Benzinga Insights

November 17, 1:35 PM

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums…

ABBV

2 minute read

Analyst Ratings

What 11 Analyst Ratings Have To Say About Mirati Therapeutics

By Benzinga Insights

November 7, 10:00 AM

Over the past 3 months, 11 analysts have published their opinion on Mirati Therapeutics (NASDAQ:MRTX) stock. These analysts…

MRTX

2 minute read

Appian To Rally Around 47%? Here Are 10 Top Analyst Forecasts For Tuesday

By Lisa Levin

November 7, 8:50 AM

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page

ALTO

2 minute read

Opdivo’s Subcutaneous Formulation Shows Promise in Advanced Kidney Cancer: Bristol Myers Squibb’s Latest Findings

By Vandana Singh

October 19, 10:25 AM

Bristol Myers Squibb Co (NYSE: BMY) released topline data from the Phase 3 CheckMate -67T noninferiority trial of a subcutaneous Opdivo (nivolumab) compared to intravenous (IV) Opdivo for advanced or metastatic clear cell renal cell carcinoma (ccRCC) who have received

BMY

11 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For October 10, 2023

By Benzinga Insights

October 10, 11:00 AM

Upgrades According to RBC Capital, the prior rating for Montrose Environmental Group Inc (NYSE:MEG) was changed from Sector…

AAP

5 minute read

Options

10 Health Care Stocks Whale Activity In Today’s Session

By Benzinga Insights

October 9, 1:35 PM

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums…

AMGN

3 minute read

Why ParaZero Technologies Shares Are Trading Higher By Over 100%? Here Are Other Stocks Moving In Monday’s Mid-Day Session

By Lisa Levin

October 9, 1:30 PM

Gainers ParaZero Technologies Ltd. (NASDAQ: PRZO) shares jumped 106% to $2.3901 after the company announced an Australian regulator approved first commercial drone flights in populated areas and near people using ParaZero safety systems.

AAOI